Given the increased focus on speed of activation of oncology studies, sponsors are under pressure to select top-performing investigative sites that can handle the challenges presented by targeted therapeutics (micro populations, mutational analysis, biomarkers, imaging and high density protocols).

Listen as Dr. Stephen Welch, Medical Oncologist at the Regional Cancer Center in London Ontario, answers questions about some of the changes his center has made to better address not only the increased complexity of oncology trials but also the economic challenges of running clinical trials. He also offers advice to oncology drug developers on why and when they should include Canada in their clinical development plans.